

INTRODUCTION TO LLS **T**HERAPY **A**CCELERATION **P**ROGRAM


April 2020

OUR MISSION

Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families



**More than \$1.3 billion
invested in research**




**Unparalleled patient
support and education
services**




**Advocacy to accelerate
cures and access**

LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients



Research by Funding Mechanism - FY19
















Therapy Acceleration Program (TAP)

- **Meeting LLS Mission is first priority**
- Strategic initiative established in 2007
- Accelerate high-risk innovative blood cancer therapeutics
- Generating ROI to further fund LLS Mission is secondary
 - Biotech Accelerator: Co-fund up to 50%
 - Academic Clinical: Co-fund 50%+

-
- The diagram is a circular chart illustrating the distribution of CAR-T cell therapy clinical trials. The outer ring is divided into four segments representing different cancer types: Leukemia (top-left, red), Lymphoma (top-right, red), Myeloma (bottom-right, red), and Solid Tumor (bottom-left, red). The inner ring is divided into five segments representing different trial phases: Preclinical (bottom, red), Phase 1 (bottom-right, red), Phase 2 (bottom-left, red), Phase 3 (top-left, red), and Approved (top-right, red). The center of the chart contains logos of various pharmaceutical companies and academic institutions involved in the trials. A red circle highlights the 'Approved' section, which includes Celator Pharmaceuticals, Kite Pharma, and Stemline. A blue circle highlights the 'Phase 3' section, which includes Forty Seven. A green circle highlights the 'Phase 2' section, which includes Forty Seven. A yellow circle highlights the 'Phase 1' section, which includes Forty Seven. A red circle highlights the 'Preclinical' section, which includes Forty Seven. A red circle highlights the 'Approved' section, which includes Celator Pharmaceuticals, Kite Pharma, and Stemline. A red circle highlights the 'Approved' section, which includes Celator Pharmaceuticals, Kite Pharma, and Stemline. A red circle highlights the 'Approved' section, which includes Celator Pharmaceuticals, Kite Pharma, and Stemline.


Studies Actively Supported by TAP

PAGE 7

THERAPY	TARGET/MODALITY	INDICATION(S)	PRECLINICAL	PHASE I	PHASE II	PHASE II REG/ PHASE III
Magrolimab Combinations	Anti-CD47 Antibody	MDS Lymphoma				MDS (+Aza) DLBCL (+Ritux) 
Cobomarsen	miR-155 Small Molecule	Cutaneous T- cell Lymphoma				
AFM13 ± Pembrolizumab	CD30/CD16A Bispecific Engager	Hodgkin Lymphoma				
Duvelisib ± Romidepsin	PI3Kδ/γ Small Molecule	Peripheral T-cell Lymphoma				
MILs	Cell Therapy	Post- transplant Myeloma				
CPI-0610	BET Small Molecule	AML/MDS Lymphoma Myeloma				
X4P-001 + Ibrutinib	CXCR4 Small Molecule	Waldenstrom Macroglobulinemia				
STRO-001	Anti-CD74 Antibody Drug Conjugate	Lymphoma Myeloma				
SEL120	CDK8/19 Small Molecule	AML				
NEXI-001	Cell Therapy	Post-transplant AML				
NK cells + ALT-803	Cell Therapy	Heme Malignancies				
CAR-37	Cell Therapy	B-cell NHL T-cell NHL				
PROTACs	IRAK4/STAT3 Small Molecule	Lymphoma				

LLS TAP Funding Is Competitive

Clinical stage therapeutics in high unmet need indications



Average annual number

Target \$2-6M dollars co-funding (equity purchase or contingent return agreement)

Typically 3-6 months to reach TAP Committee Review

- **Subcommittee of LLS National Board**
- Members consist of KOLs, IP lawyer, VC-investors in biotech, Industry veterans
- TAP Research performs S&E and recommends TAP projects to the Committee
- Company presents to the TAP Committee
- The Committee may approve, conditionally approve or reject company funding request
- Committee approval provides Research BD to proceed to Term Sheet and then formal Agreement

Key Criteria

- **High Unmet Medical Need**
- Innovative Science
- First-in-Class
- High potential to impact clinical practice
- Clinical PoC Study or Registration-Directed Study
- Strong IP Position
- Competent Management Team
- Solid Corporate Finance

Why Companies Come to TAP in addition to \$\$


- Deep knowledge of blood cancer landscape
- Expertise in hem/onc clinical development within LLS and via KOLs
- Connections to patients
- Advocacy efforts for patients
- Biotech companies leverage LLS approval to raise additional funds
- Track record of success

TAP Impact

- Deliver new and better treatments to patients
- Influence clinical practice for patient benefits
- Incentivize companies to study innovative & promising therapeutics in hematological indications in the clinic for PoC or regulatory approval
- Help attract more funding to TAP partners for them to continue development of promising therapeutics
- Generate monetary returns for LLS Mission

TAP is Bridging the Gap for Biotech

PAGE 13



BEATING CANCER IS IN OUR BLOOD.



LEUKEMIA & LYMPHOMA SOCIETY®



THANK YOU

We have one goal: A world without blood cancers

